Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Lupin Limited
Latuda Enters ‘Twilight’ Phase Pending Generic Competition
A swathe of generic lurasidone launches following the originator’s US patent expiry may trigger a shift in the antipsychotics space.
Lupin Builds Momentum As It Anticipates FDA Action On Spiriva Rival
Lupin has offered further specifics on expected FDA action for its proposed Spiriva generic, as the Indian firm reported a solid third financial quarter that saw an uptick in sales and profits, including turnover growth in the US.
India M&As Overtook PE Activity In 2022, Deal Momentum To Continue In 2023
India had a busy deals calendar in 2022, with companies led by Biocon striking large M&A deals while PE activity declined. In Vivo's sister publication Scrip pieced together data for infographics on these deals. A multitude of factors is expected to keep the momentum going in 2023.
Deals, Divestitures In Store As Dr Reddy’s Stays Course To Top Five India League
Investments in differentiated and specialty products and collaborations, alongside divestitures, are part of Dr Reddy’s plans as it seeks to move up the rankings in India. Momentum in China, including an alliance with Sunflower Pharma for orphan diseases, is also being keenly watched.
- Drug Delivery
- Generic Drugs
- Specialty Pharmaceuticals
- Controlled Release
Drug Discovery Tools
- Natural Products
- Molecular Diversity
- Drug Discovery Tools
- Other Names / Subsidiaries
- Generic Health Pty Ltd
- Temmler Pharma GmbH & Co.
- YL Biologics (YLB)
- ZAO Biocom
- Kyowa Pharmaceutical Industry Co., Ltd.
- Southern Cross Pharma Pty Ltd
- Symbiomix Therapeutics, LLC.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.